Barclays Raises Hims & Hers (HIMS) Target to $29 After Novo Deal Clears Legal Overhang — Canaccord Cuts Progyny (PGNY) on Cautious 2026 Outlook

10 hours ago 1

David Moadel

Wed, March 11, 2026 astatine 9:10 AM CDT 7 min read

Hims & Hers Health (HIMS) reached $2.347 cardinal successful full-year revenue, up 59% year-over-year, with a subscriber basal crossing 2.5 cardinal and monthly gross per subscriber astatine $83. Progyny (PGNY) posted $1.289 cardinal successful full-year 2025 revenue, up 10.4% year-over-year, with grounds adjusted EBITDA of $222.09 cardinal and zero debt.
Hims secured a landmark organisation statement with Novo Nordisk that removed a important ineligible overhang and cleared the way for accelerated growth, portion Progyny faces a crisp deceleration successful 2026 guidance with lone 5% to 9% projected gross maturation compared to 10.4% successful 2025.
The expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks. Get them present FREE.

Two healthcare names are drafting caller expert attraction this week arsenic Wall Street recalibrates astir a landmark GLP-1 truce and a fertility benefits institution navigating a murky 2026 outlook. Barclays expert Glen Santangelo raised his terms people connected Hims & Hers Health to $29 from $25, keeping an Overweight rating, aft the company's woody with Novo Nordisk removed a important ineligible unreality from the stock. Meanwhile, Canaccord trimmed its terms people connected Progyny (NASDAQ:PGNY) to $19 from $26 portion maintaining a Hold, citing unchangeable but uncertain concern trends pursuing Q4 results. Hims & Hers Health (NYSE:HIMS) is the different sanction successful absorption this week.

Ticker

Company

Firm

Old → New Rating

New Price Target

One-Line Takeaway

HIMS	Hims & Hers Health	Barclays	Overweight → Overweight	$29 (from $25)	Legal overhang cleared; Barclays sees marketplace underpricing caller merchandise opportunity
PGNY	Progyny	Canaccord	Hold → Hold	$19 (from $26)	Stable trends but cautious guidance keeps expert connected the sidelines

Santangelo's enactment frames the Novo Nordisk statement arsenic a dual catalyst. The rally pursuing the woody highlights the incremental marketplace accidental and removal of the ineligible overhang for Hims & Hers shares, the expert told investors. Beyond the woody itself, Barclays argues the marketplace is inactive underappreciating Hims' accidental from caller products -- a awesome that the steadfast sees the stock's caller betterment arsenic conscionable the opening of a re-rating, not the extremity of it.

The woody itself resolved a suit Novo Nordisk filed successful February aft Hims launched and past pulled a compounded mentation of the Wegovy pill. Under the caller arrangement, Hims volition administer approved Ozempic and Wegovy injectables, arsenic good arsenic the oral Wegovy pill, astatine Novo's self-pay prices connected its platform, portion agreeing to halt advertizing compounded GLP-1 drugs extracurricular of clinically indispensable cases. The FDA publically endorsed the resolution, with commissioner Marty Makary calling the woody a triumph for entree and affordability.

Read Entire Article